Company

Rhinomed Limited

Headquarters: Richmond, VIC, Australia

CEO: Mr. Michael Johnson

ASX: RNO

Market Cap

A$8.6 Million

AUD as of Jan. 1, 2024

US$5.8 Million

Market Cap History

Rhinomed Limited market capitalization over time

Evolution of Rhinomed Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Rhinomed Limited

Detailed Description

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It identifies, acquires, and commercializes nasal stent delivery technologies. The company's product portfolio includes Turbine for enhanced breathing in sports; Mute, an anti-snoring device; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. It also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Rhinomed Limited has the following listings and related stock indices.


Stock: ASX: RNO wb_incandescent

Details

Headquarters:

132 Gwynne Street

Level 1 Cremorne

Richmond, VIC 3121

Australia

Phone: 61 3 8416 0900

Fax: 61 3 8080 0796